financetom
Business
financetom
/
Business
/
BHP shares fall 3.6% after making $39 billion bid for rival Anglo American
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BHP shares fall 3.6% after making $39 billion bid for rival Anglo American
Apr 25, 2024 5:26 PM

(Reuters) - BHP Group ( BHP ) shares fell 3.6% on Friday in the first day of trading since revealing a $38.8 billion bid for smaller rival Anglo American in a deal that would forge the world's largest copper miner.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intuitive Surgical Insider Sold Shares Worth $741,398, According to a Recent SEC Filing
Intuitive Surgical Insider Sold Shares Worth $741,398, According to a Recent SEC Filing
Apr 24, 2024
02:26 PM EDT, 04/24/2024 (MT Newswires) -- Alan J Levy, Director, on April 23, 2024, sold 2,000 shares in Intuitive Surgical ( ISRG ) for $741,398. Following the Form 4 filing with the SEC, Levy has control over a total of 25,319 shares of the company, with 25,319 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1035267/000103526724000141/xslF345X03/edgardoc.xml Price: 373.64, Change: -3.44, Percent Change:...
Top Midday Gainers
Top Midday Gainers
Apr 24, 2024
02:25 PM EDT, 04/24/2024 (MT Newswires) -- BranchOut Food ( BOF ) said Wednesday it has expanded its relationship with the nation's largest retailer, bringing the total annualized value of commitments from the retailer to over $8.0 million annually. Shares surged 59% as intraday trading volume climbed to more than 100.6 million versus a daily average of about 72,000. B....
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Apr 24, 2024
Nine months after the U.S. launch of Eisai Limited (OTC:ESALY) and Biogen Inc’s Leqembi, the first drug shown to slow Alzheimer’s progression, adoption faces hurdles due to skepticism among some doctors.  Initially hopeful, Alzheimer’s experts anticipated challenges with Leqembi’s requirements, including frequent infusions and diagnostic tests, leading to slow adoption after FDA approval.  Interviews with 20 neurologists and geriatricians revealed concerns about efficacy, costs, and...
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
Apr 24, 2024
April 24 (Reuters) - A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States. Senator Bernie Sanders, chair of the Senate Committee on Health, Education, Labor and Pensions, sent a letter to Novo's CEO seeking more information on U.S. prices...
Copyright 2023-2026 - www.financetom.com All Rights Reserved